NAD+ and NMN: Cellular Energy and the Science of Aging

Few molecules in modern biochemistry have generated as much excitement — or as much debate — as nicotinamide adenine dinucleotide (NAD+). Present in every living cell, NAD+ sits at the crossroads of energy metabolism, DNA repair, gene regulation, and cellular defense. As researchers have discovered that NAD+ levels decline dramatically with age, a new frontier of longevity science has emerged, centered on the question of whether replenishing this critical coenzyme can slow, halt, or even reverse aspects of biological aging. Nicotinamide mononucleotide (NMN), a direct precursor to NAD+, has become one of the most widely studied and commercially popular supplements in this rapidly evolving field.

This article provides a comprehensive examination of NAD+ biology, the science behind NMN supplementation, the current state of human clinical research, and practical guidance for those considering these interventions. As with all health information, readers should consult qualified healthcare professionals before beginning any supplement regimen.

Table of Contents

1. Overview — The Molecule at the Center of the Longevity Revolution
2. What Is NAD+
3. NAD+ Decline with Age
4. NMN vs NR — The Precursor Debate
5. David Sinclair's Research and the Sirtuin Theory
6. How NAD+ Works — Energy Metabolism, DNA Repair, Sirtuins, PARPs, and CD38
7. Mitochondrial Function
8. Anti-Aging and Cellular Repair
9. Cognitive Function and Brain Health
10. Cardiovascular Health
11. Metabolic Health and Insulin Sensitivity
12. Exercise Performance
13. Immune Function
14. Fertility and Reproductive Aging
15. Circadian Rhythm Regulation
16. The Human Clinical Trials
17. IV NAD+ Therapy
18. Sublingual NMN vs Oral Supplementation
19. Dosage and Timing
20. Synergistic Supplements — Resveratrol, TMG, and Quercetin
21. Safety and Side Effects
22. Regulatory Status
23. References

1. Overview — The Molecule at the Center of the Longevity Revolution

The pursuit of longevity is as old as civilization, but it has never been informed by science as deeply as it is today. At the heart of modern aging research lies NAD+, a coenzyme that participates in more than 500 enzymatic reactions in the human body. Without adequate NAD+, cells cannot efficiently produce energy, repair damaged DNA, regulate gene expression, or mount effective defenses against oxidative stress. The discovery that NAD+ levels plummet with age — declining by approximately 50 percent between young adulthood and middle age — has ignited a global research effort to understand whether restoring youthful NAD+ levels can meaningfully extend both healthspan and lifespan.

NMN has emerged as one of the most promising NAD+ precursors, joining nicotinamide riboside (NR) and niacin in the family of vitamin B3 derivatives that the body can convert into NAD+. Hundreds of preclinical studies in mice and other model organisms have demonstrated that NMN supplementation can reverse age-related physiological decline in muscle, brain, heart, liver, kidney, and immune tissues. Human clinical trials, while still in relatively early stages, have begun to confirm that NMN can safely raise blood NAD+ levels in people and are beginning to reveal functional benefits.

The field has attracted both rigorous scientific investigation and considerable commercial hype. Distinguishing between well-supported findings and premature marketing claims is essential for anyone seeking to make informed decisions about NAD+ supplementation. This article aims to provide that distinction, grounded in peer-reviewed research and the most current evidence available through early 2026.

2. What Is NAD+

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells. It was first discovered in 1906 by British biochemists Arthur Harden and William John Young, who noticed that adding a boiled and filtered yeast extract greatly accelerated alcoholic fermentation in unboiled yeast extracts. They named this heat-stable but unidentified factor cozymase. Nearly 25 years later, Hans von Euler-Chelpin established its chemical composition as containing an adenine, a reducing sugar group, and a phosphate. In 1936, German scientist Otto Heinrich Warburg demonstrated the function of this nucleotide coenzyme in hydride transfer and identified the nicotinamide portion as the site of redox reactions — work that would prove foundational to our understanding of cellular energy production.

Structurally, NAD+ is a dinucleotide, meaning it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine base, and the other contains nicotinamide, a form of vitamin B3. NAD+ exists in two forms: the oxidized form (NAD+) and the reduced form (NADH). The interconversion between these two forms is central to the metabolic machinery of every cell. In its oxidized form, NAD+ accepts electrons from metabolic reactions; in its reduced form, NADH donates those electrons to the mitochondrial electron transport chain, ultimately driving the production of adenosine triphosphate (ATP), the primary energy currency of the cell.

Beyond its role in energy metabolism, NAD+ functions as a critical signaling molecule. It serves as a substrate for three major classes of enzymes: sirtuins (protein deacetylases that regulate gene expression and DNA repair), poly(ADP-ribose) polymerases (PARPs, which detect and facilitate DNA repair), and cyclic ADP-ribose synthases such as CD38 and CD157 (which regulate calcium signaling and immune function). Each time one of these enzymes uses NAD+, the molecule is consumed and must be regenerated through biosynthetic pathways, making the supply and demand of NAD+ a central determinant of cellular health.

3. NAD+ Decline with Age

One of the most consequential discoveries in aging biology over the past two decades is that NAD+ levels decline substantially with age across virtually every tissue examined, including skin, blood, liver, muscle, and brain. By the time a person reaches middle age, their NAD+ levels may have fallen to roughly half of what they were in youth. By older age, the decline can be even more precipitous. This progressive depletion has been linked to many of the hallmarks of aging, including mitochondrial dysfunction, genomic instability, cellular senescence, chronic inflammation, and impaired stem cell function.

The decline occurs through a combination of reduced synthesis and increased consumption. On the synthesis side, the activity of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway, decreases with age. Chronic inflammation, which rises with aging in a process known as inflammaging, suppresses NAMPT expression through elevated oxidative stress and inflammatory cytokines. On the consumption side, aging is associated with increased activity of CD38, a NADase enzyme expressed on immune cells. Research published in Cell Metabolism has demonstrated that CD38 expression and activity increase with age, and that CD38 is a primary driver of age-related NAD+ decline. Additionally, as DNA damage accumulates with age, PARP enzymes consume increasing quantities of NAD+ in their efforts to repair the genome, further depleting the cellular pool.

The consequences of this decline are profound and far-reaching. Reduced NAD+ availability impairs sirtuin function, which in turn compromises the cell's ability to maintain epigenetic integrity, repair DNA, resist stress, and regulate metabolism. Mitochondria, which depend on NAD+ for the electron transport chain, produce less ATP and generate more reactive oxygen species. This creates a vicious cycle in which NAD+ depletion accelerates the very processes that drive further depletion, contributing to the progressive functional decline that characterizes aging.

4. NMN vs NR — The Precursor Debate

The two most widely studied and commercially available NAD+ precursors are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both are forms of vitamin B3 that the body can convert into NAD+, but they differ in molecular structure, metabolic pathways, tissue distribution, and the extent of their clinical evidence base. The question of which precursor is superior has generated substantial scientific debate and commercial rivalry.

Structurally, NMN and NR are nearly identical except that NMN contains an additional phosphate group, making it a slightly larger molecule. In the biosynthetic pathway, NR is phosphorylated by NR kinases (NRK1 and NRK2) to form NMN, which is then converted to NAD+ by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase). NMN, being one step closer to NAD+ in this pathway, can be directly converted to NAD+ by NMNAT without the intermediate phosphorylation step required by NR. In the salvage pathway, the body synthesizes NMN from nicotinamide via the enzyme NAMPT.

Absorption mechanisms also differ. The discovery of Slc12a8, a specific NMN transporter in the small intestine, provided evidence that NMN can be directly absorbed into the bloodstream without prior conversion to NR. Studies suggest that NMN raises NAD+ levels in a broad range of tissues including muscle, heart, brain, kidneys, and blood vessels. NR, by contrast, appears to most effectively boost NAD+ in the liver and blood but has shown limited impact on other tissues. However, a 2024 study in Science Advances revealed additional complexity: much of orally administered NMN and NR undergoes gut microbiota-mediated deamidation and conversion to nicotinic acid before entering the NAD+ synthesis pathway, suggesting that both precursors may ultimately raise NAD+ through similar downstream mechanisms.

A January 2026 clinical trial involving 65 healthy adults found that both NR and NMN doubled circulating NAD+ levels over 14 days, while plain nicotinamide (NAM) did not achieve the same effect. The majority of published human clinical trials have used NR, which has a longer history of clinical study. NMN's human evidence base, while growing rapidly, remains younger but is accumulating encouraging results. Both precursors appear safe and well tolerated at commonly used doses.

5. David Sinclair's Research and the Sirtuin Theory

No figure has done more to popularize NAD+ science than David A. Sinclair, a tenured Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. Sinclair obtained his Ph.D. in Molecular Genetics at the University of New South Wales in 1995 and conducted postdoctoral research at MIT with Dr. Leonard Guarente, where he co-discovered a cause of aging in yeast and first identified the role of Sir2 (the yeast homolog of mammalian sirtuins) in epigenetic changes driven by genome instability.

The Sinclair Lab was the first to identify a role for NAD+ biosynthesis in the regulation of lifespan and the first to demonstrate that sirtuins mediate the benefits of caloric restriction in mammals. Sirtuins are a family of seven enzymes (SIRT1 through SIRT7) that use NAD+ as a cofactor to remove acetyl groups from proteins, a process called deacetylation. This activity allows sirtuins to regulate gene expression, maintain epigenetic integrity, promote DNA repair, control inflammation, and coordinate metabolic responses to nutrient availability. Mice engineered to express additional copies of SIRT1 or SIRT6, or treated with sirtuin-activating compounds such as resveratrol and SRT2104, showed improved organ function, physical endurance, disease resistance, and extended longevity.

Sinclair's work on SIRT1 led to an important finding: the level of NAD+, a required cofactor for SIRT1, declines with age. This observation provided a mechanistic explanation for why sirtuin activity decreases in aging tissues and suggested that boosting NAD+ levels could restore sirtuin function and its protective effects. The Sinclair Lab has since developed an active program to identify novel molecules that raise NAD+ levels and is testing them for their effects on aging and age-related diseases, with human clinical trials of NAD+-boosting molecules ongoing. Sinclair's Information Theory of Aging proposes that aging is fundamentally driven by the loss of epigenetic information — the cell's ability to read its own DNA correctly — and that this process may be reversible through interventions that restore the epigenetic landscape, including NAD+ repletion.

6. How NAD+ Works — Energy Metabolism, DNA Repair, Sirtuins, PARPs, and CD38

NAD+ operates through several distinct but interconnected mechanisms that collectively determine cellular health and resilience. Understanding these mechanisms is essential for appreciating both the promise and the complexity of NAD+ interventions.

Energy Metabolism

In its most fundamental role, NAD+ functions as an electron carrier in metabolic pathways. During glycolysis and the citric acid cycle, NAD+ accepts electrons from fuel molecules (glucose, fatty acids, amino acids) to become NADH. NADH then donates those electrons to Complex I of the mitochondrial electron transport chain, driving the flow of protons across the inner mitochondrial membrane and powering ATP synthase. Without sufficient NAD+, these pathways slow, ATP production falls, and cells cannot meet their energy demands.

DNA Repair via PARPs

Poly(ADP-ribose) polymerases, particularly PARP1 and PARP2, are DNA damage sensors that detect single-strand and double-strand breaks faster than any other repair mechanism. When PARP1 binds to damaged DNA, it uses NAD+ to synthesize chains of poly(ADP-ribose) that serve as signals to recruit additional repair machinery. This process is essential for maintaining genomic stability, but it comes at a significant cost: under severe genotoxic stress, PARP activation can deplete cellular NAD+ to a fraction of basal levels within minutes. In aging tissues, where DNA damage accumulates continuously, chronic PARP activity is a major driver of NAD+ consumption.

Gene Regulation via Sirtuins

The seven mammalian sirtuins (SIRT1–SIRT7) are NAD+-dependent deacetylases that regulate a vast array of cellular processes. SIRT1 and SIRT6 are particularly important for DNA repair and epigenetic maintenance. SIRT3, located in the mitochondria, regulates the electron transport chain and antioxidant defenses. SIRT1 also promotes autophagy (the cellular recycling process), reduces inflammation by deacetylating NF-kB, and coordinates metabolic adaptation to fasting and caloric restriction. Because sirtuins require NAD+ as a substrate and because they compete with PARPs for the same NAD+ pool, declining NAD+ levels with age directly impair sirtuin function.

CD38 — The NAD+ Consumer

CD38 is an ectoenzyme (surface enzyme) that degrades NAD+ to produce cyclic ADP-ribose and nicotinamide. While CD38 plays important roles in calcium signaling and immune cell activation, its expression and activity increase markedly with age, particularly in inflammatory immune cells. Research published in Cell Metabolism demonstrated that CD38 is required for the age-related decline in NAD+ and that this decline drives mitochondrial dysfunction through a pathway mediated by reduced SIRT3 activity. Inhibiting CD38 or reducing chronic inflammation may therefore be as important as supplementing with NAD+ precursors for maintaining optimal NAD+ levels.

7. Mitochondrial Function

Mitochondria are often described as the powerhouses of the cell, and their function is intimately dependent on NAD+ availability. NAD+ is required for the electron transport chain, where NADH donates electrons to Complex I to generate the proton gradient that drives ATP synthesis. Beyond direct energy production, NAD+ also regulates mitochondrial biogenesis (the creation of new mitochondria), mitophagy (the selective removal of damaged mitochondria), and the expression of mitochondrial-encoded proteins. When NAD+ levels fall, fewer electrons flow through the chain, ATP production declines, and more reactive oxygen species (ROS) leak from the electron transport chain, causing oxidative damage to mitochondrial DNA, lipids, and proteins.

The Sinclair Lab made an important contribution by discovering that miscommunication between the mitochondrial and nuclear genomes is a cause of age-related physiological decline. The two genomes must coordinate to produce the protein complexes of the electron transport chain, and NAD+ signaling through SIRT1 and PGC-1 alpha (peroxisome proliferator- activated receptor gamma coactivator 1-alpha) is essential for this coordination. When NAD+ declines, the nuclear genome's signals to mitochondria are disrupted, leading to mismatched protein production and dysfunctional respiratory complexes. In preclinical studies, NMN supplementation has been shown to restore mitochondrial function in aged mice, increasing oxygen consumption, improving fatty acid oxidation, and reducing ROS production in muscle, liver, and heart tissues.

Human evidence is beginning to emerge as well. Clinical trials have shown that NMN supplementation increases blood NAD+ levels and its metabolites, which is a prerequisite for improved mitochondrial function. While direct measurements of mitochondrial function in human supplementation trials remain limited, the improvements in exercise capacity, insulin sensitivity, and muscle function observed in some trials are consistent with enhanced mitochondrial performance.

8. Anti-Aging and Cellular Repair

The concept of anti-aging through NAD+ repletion rests on a compelling biological rationale: if declining NAD+ levels are a driver of multiple hallmarks of aging, then restoring those levels should slow or partially reverse age-related cellular damage. Preclinical evidence strongly supports this hypothesis. In aged mice, NMN supplementation has been shown to improve stem cell function, reduce cellular senescence (the accumulation of dysfunctional cells that secrete inflammatory molecules), enhance DNA repair capacity, restore epigenetic patterns, and improve organ function across multiple tissues.

A key mechanism is the activation of sirtuins, particularly SIRT1 and SIRT6. SIRT1 promotes autophagy, the cellular process by which damaged organelles, misfolded proteins, and other cellular debris are recycled. Autophagy declines with age and its impairment is considered a hallmark of aging. By restoring NAD+ levels and reactivating SIRT1, NMN supplementation may reinvigorate the cell's housekeeping machinery. SIRT6, meanwhile, plays a critical role in maintaining telomere integrity and facilitating efficient DNA double-strand break repair through homologous recombination. Mice overexpressing SIRT6 live significantly longer than wild-type controls.

The Sinclair Lab's Information Theory of Aging adds another dimension to this picture. According to this framework, aging is fundamentally an epigenetic phenomenon: cells lose the ability to read their DNA correctly because epigenetic marks (the chemical modifications that tell each cell which genes to express) become scrambled over time. DNA breaks, which recruit sirtuins away from their normal epigenetic maintenance duties to help with emergency repair, are a primary cause of this epigenetic noise. By boosting NAD+ and enhancing sirtuin activity, the theory suggests, it may be possible to restore the epigenetic landscape to a more youthful state. While this remains an active area of research and has not yet been proven in humans, the preclinical evidence is generating significant scientific interest.

9. Cognitive Function and Brain Health

The brain is one of the most metabolically active organs in the body, consuming approximately 20 percent of total energy despite representing only about 2 percent of body weight. This extraordinary energy demand makes the brain particularly vulnerable to NAD+ depletion. Declining NAD+ levels in the brain have been associated with impaired mitochondrial function in neurons, reduced cerebrovascular blood flow, increased neuroinflammation, and the accumulation of hallmark proteins associated with neurodegenerative diseases including amyloid-beta plaques and tau tangles.

Preclinical evidence for NMN's neuroprotective effects is substantial. In aged mice, NMN supplementation rescued cerebromicrovascular endothelial function and neurovascular coupling responses — the mechanism by which blood flow increases to active brain regions — and significantly improved spatial working memory and gait coordination. In mouse models of Alzheimer's disease, NMN treatment reduced the accumulation of amyloid-beta in the brain, inhibited neuronal apoptosis, decreased neuroinflammation, and improved cognitive performance measured by the Morris water maze. NMN has also demonstrated protective effects in models of traumatic brain injury, alleviating neurological impairment through anti-neuroinflammatory mechanisms. Additionally, research suggests that NMN may improve cognitive function in Alzheimer's models partly by modulating the gut-brain axis through beneficial changes to the intestinal microbiota.

Human evidence remains limited. In a double-blind, randomized controlled trial of 20 healthy older men, NMN treatment at 250 mg daily for 12 weeks significantly increased blood NAD+ levels and NAD+ metabolite concentrations but did not produce statistically significant improvements in overall cognitive function as measured by standard cognitive assessments. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment also showed NAD+ elevation without clear cognitive benefits over the study period. These results suggest that either longer treatment durations, higher doses, or enrollment of individuals with more pronounced cognitive decline may be necessary to detect benefits. The human trials conducted to date have generally been too short and too small to demonstrate clinical benefit in cognitive decline or dementia prevention, but the preclinical foundation remains strong and larger trials are warranted.

10. Cardiovascular Health

The heart is among the most energy-demanding organs in the body, beating approximately 100,000 times per day and depending heavily on mitochondrial oxidative phosphorylation for its ATP supply. NAD+ is essential for cardiac energy metabolism, and its decline with age is associated with increased cardiovascular risk. Research has shown that NAD+ levels decrease with age, obesity, and hypertension — all major risk factors for cardiovascular disease. In hypertensive patients, immune cell NAD+ levels were found to be 44 percent lower than in healthy controls, with lower NAD+ levels correlating with higher blood pressure, greater arterial stiffness, and reduced endothelial function.

Preclinical studies have demonstrated that boosting NAD+ levels through supplementation with NMN or NR can improve multiple aspects of cardiovascular health. The therapeutic elevation of NAD+ reduces chronic low-grade inflammation, reactivates autophagy and mitochondrial biogenesis, and enhances oxidative metabolism in vascular cells. In animal models, NAD+ boosting has been shown to improve atherosclerosis, ischemic cardiomyopathy, diabetic cardiomyopathy, arrhythmogenic cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and various modalities of heart failure. Decreased NAD+ levels in heart muscle cells lead to inadequate ATP production and increased susceptibility to heart failure.

Human clinical data are emerging. A pilot study demonstrated that supplementation with nicotinamide riboside for six weeks produced a mild but measurable reduction in systolic blood pressure and aortic stiffness in healthy middle-aged and older adults. A Harvard-affiliated study found that NMN significantly reduced diastolic blood pressure and body weight in middle-aged and older overweight and obese adults. A meta-analysis of randomized controlled trials examining NAD+ precursors found trends toward improved blood pressure and reduced C-reactive protein concentration, though the evidence base remains small and larger trials are needed to confirm these cardiovascular benefits in humans.

11. Metabolic Health and Insulin Sensitivity

The relationship between NAD+ and metabolic health has been one of the most actively studied areas in NAD+ biology. NAD+ is central to glucose and lipid metabolism, and its decline with age has been implicated in the development of insulin resistance, metabolic syndrome, and type 2 diabetes. Sirtuins, particularly SIRT1 and SIRT3, play critical roles in regulating insulin signaling, glucose uptake in muscle, hepatic gluconeogenesis, and fatty acid oxidation — all processes that depend on adequate NAD+ availability.

The most notable human finding in this area came from a landmark study published in Science in 2021, which found that NMN supplementation increased muscle insulin sensitivity in prediabetic women. Participants receiving NMN showed enhanced insulin-stimulated glucose disposal and improved skeletal muscle insulin signaling, along with upregulated expression of platelet-derived growth factor receptor beta and other genes related to muscle remodeling. This was the first rigorous human demonstration of metabolic benefit from NMN supplementation and generated significant excitement in the field.

However, subsequent meta-analyses have painted a more nuanced picture. A 2024 systematic review and meta-analysis of eight randomized controlled trials involving 342 middle-aged and older adults, with NMN dosages ranging from 250 to 2,000 mg per day for 14 days to 12 weeks, found no statistically significant improvements in fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance (HOMA-IR), or lipid profiles. This contrasts with the dramatic metabolic benefits seen consistently in animal models. The discrepancy may reflect differences in dosing, duration, study population, or the inherent difficulty of detecting metabolic improvements in short-term trials. Future research may reveal sex-specific or population-specific effects, as suggested by the positive results in prediabetic women.

12. Exercise Performance

Exercise capacity is one of the strongest predictors of overall health and longevity, and the potential for NAD+ boosting to enhance physical performance has attracted considerable interest. The theoretical basis is sound: NMN supports mitochondrial biogenesis through the SIRT1/PGC-1 alpha pathway, increases ATP production, and improves the efficiency of muscle energy metabolism. More mitochondria and better-functioning mitochondria should translate to greater endurance capacity and faster recovery.

A key human study examined the effects of six weeks of NMN supplementation combined with endurance exercise training in amateur runners. The results showed that NMN enhanced ventilatory threshold, oxygen uptake at submaximal intensities, and the percentage of maximal oxygen consumption (VO2max) at which participants could work, though it did not increase VO2max itself, maximal ventilation, oxygen pulse, or peak power output. A dose-response pattern emerged: submaximal exercise performance improved in the medium-dose (600 mg) and high-dose (1,200 mg) groups compared to the control group, but the lower dose did not produce significant effects. NMN supplementation up to 1,200 mg per day was safe and well tolerated throughout the study.

A February 2026 trial in healthy men provided further evidence, finding that NMN reduced inflammatory markers after intense exercise, suggesting potential benefits for recovery. These results indicate that NMN may be most beneficial for submaximal, sustained endurance performance rather than peak power or maximal capacity, and that higher doses may be needed to achieve ergogenic effects. For recreational athletes and aging individuals seeking to maintain exercise capacity, NMN supplementation combined with regular training may offer synergistic benefits, though more research is needed to optimize dosing protocols and identify which populations benefit most.

13. Immune Function

The aging immune system undergoes a process known as immunosenescence, characterized by declining function of both innate and adaptive immunity, reduced pathogen defense, impaired cancer surveillance, and diminished vaccine responses. Simultaneously, aging drives inflammaging — a state of chronic, low-grade inflammation that contributes to frailty and the development of age-related diseases including cardiovascular disease, neurodegeneration, and cancer. NAD+ metabolism is deeply entwined with both of these processes.

Research has demonstrated that NAD+ generation via the kynurenine pathway and the salvage pathway regulates macrophage immune function in aging and inflammation. Macrophages, the front-line immune cells responsible for engulfing pathogens and coordinating inflammatory responses, depend on adequate NAD+ for their metabolic flexibility and functional capacity. The de novo NAD+ synthesis pathway specifies innate immune function, and disruption of this pathway impairs macrophage activation and pathogen clearance. With aging, increased expression of CD38 on inflammatory immune cells depletes the NAD+ pool, further compromising immune cell function and creating a positive feedback loop between inflammation and NAD+ depletion.

Preclinical studies have shown that dietary supplementation with NMN, NR, or nicotinamide can boost NAD+ levels and restore sirtuin activity in aged mice, leading to improved immune responses. Geroprotective strategies including rapamycin, metformin, and NAD+ boosters have been shown to reduce the severity and lethality of infections in animal models, though their clinical benefits in humans remain modest and context-dependent. NAD+ supplementation has been proposed as a strategy to address immunosenescence and support immune resilience in older adults, particularly in the context of respiratory infections and vaccine responses, but human clinical data specifically examining immune outcomes remain scarce and represent an important area for future investigation.

14. Fertility and Reproductive Aging

One of the most striking preclinical findings in NAD+ research involves female fertility. Reproductive aging in women is characterized by a decline in both the quantity and quality of oocytes (eggs), leading to reduced fertility, increased rates of chromosomal abnormalities, and higher risks of miscarriage. This decline accelerates dramatically after age 35 and is accompanied by falling NAD+ levels in ovarian tissue. Research published in Cell Reports demonstrated that NAD+ repletion rescues female fertility during reproductive aging in mice, with NMN supplementation reversing the declining quality of maternally aged oocytes.

The mechanism appears to involve restoration of mitochondrial function in oocytes. Aged oocytes exhibit impaired mitochondrial membrane potential, reduced ATP production, and elevated reactive oxygen species — all of which contribute to poor egg quality and developmental failure after fertilization. NMN supplementation restores mitochondrial function in these aged oocytes, eliminates accumulated ROS, and suppresses apoptosis, leading to improved fertilization rates and embryo development. Long-term NMN administration has also shown anti-aging effects in ovaries, increasing ovarian NAD+ levels, inhibiting ovarian atrophy, enhancing hormone secretion, and improving both the quality and quantity of ovulatory oocytes. A synthesis of seven preclinical studies demonstrated that NMN consistently improved oocyte and ovarian function across models of metabolic, exogenous, and age-associated stress.

These findings have generated enormous interest in the fertility medicine community, and NMN is increasingly being discussed as a potential adjunct supplement for women undergoing in vitro fertilization (IVF), particularly those of advanced maternal age. However, it is important to emphasize that direct studies on NMN and human oocyte quality are limited, and researchers caution that NMN supplements should not be taken by women wishing to become pregnant until further human studies have been completed. The animal results, while remarkable — with researchers reporting the ability to revert mouse eggs to a quality equivalent to decades younger in human terms — require validation in human clinical trials before clinical recommendations can be made.

15. Circadian Rhythm Regulation

NAD+ metabolism and the circadian clock are intimately linked through an elegant feedback mechanism that has profound implications for health and aging. Intracellular NAD+ levels oscillate with a 24-hour rhythm, driven by the circadian clock machinery. The core clock transcription factors CLOCK and BMAL1 regulate the circadian expression of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway. As NAMPT expression rises and falls over the course of the day, so too do intracellular NAD+ levels.

This creates a self-reinforcing feedback loop. NAD+ activates SIRT1, which is recruited to the NAMPT promoter and contributes to the circadian synthesis of its own coenzyme. SIRT1 also deacetylates PER2, a core clock protein, modulating circadian amplitude. Additionally, SIRT1 deacetylates BMAL1, PARP1 mediates ADP-ribosylation of CLOCK, and SIRT6 facilitates the recruitment of CLOCK:BMAL1 to circadian gene promoters. The net result is that NAD+ is not merely a passive metabolic currency but an active regulator of the molecular clock itself. Inhibition of NAMPT promotes oscillation of the clock gene Per2 by releasing CLOCK:BMAL1 from suppression by SIRT1, completing the feedback loop.

The disruption of this NAD+-circadian axis with aging may contribute to the sleep disturbances, metabolic dysregulation, and impaired tissue repair observed in older adults. Interestingly, NAMPT-dependent NAD+ biosynthesis controls circadian metabolism in a tissue-specific manner: NAMPT oscillates in several adipose (fat) depots in both mice and primates, but this oscillation is absent in skeletal muscle, suggesting that the feedback cycle may not be a rhythmic driver of circadian machinery in all tissues. The implication for supplementation timing is significant: taking NMN in the morning may align with the natural circadian peak of NAD+ metabolism and optimize its integration with the body's internal clock.

16. The Human Clinical Trials

The evidence base for NMN in humans has grown substantially in recent years, with multiple randomized, double-blind, placebo-controlled trials now completed. While no single trial has yet demonstrated the dramatic rejuvenation effects seen in animal studies, the collective findings are informative and cautiously encouraging.

Metro International Biotech MIB-626 Trial

One of the most rigorous NMN trials was conducted by researchers from Harvard Medical School's Brigham and Women's Hospital using MIB-626, a pharmaceutical-grade NMN tablet developed by Metro International Biotech. In this study, 32 overweight or obese adults aged 55 to 80 received 1,000 mg of MIB-626 once daily or twice daily for two weeks. The results showed that MIB-626 safely and substantially doubled NAD+ blood levels in a dose-dependent manner. The 1,000 mg dose taken once or twice daily for 14 days was safe and well tolerated, with no serious adverse events and mild adverse events similar among all groups including placebo.

The Uthever Multicenter Trial

A multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Uthever, a commercially available NMN supplement, in middle-aged and older adults. At day 60, NAD+/NADH levels increased by 38 percent compared to baseline in the NMN group, versus a 14.3 percent increase in the placebo group. Participants taking NMN performed significantly better than those receiving placebo in health scoring systems and on a six-minute walking endurance test, providing some of the first functional outcome data in humans.

The Insulin Sensitivity Trial

Published in Science, this landmark trial in prediabetic women demonstrated that NMN supplementation increased muscle insulin sensitivity and insulin-stimulated glucose disposal, representing the first rigorous demonstration of metabolic benefit from NMN in humans. While subsequent meta-analyses have not confirmed broad metabolic benefits across diverse populations, this trial remains an important proof-of-concept that NMN can produce clinically meaningful physiological changes in humans.

Across all completed trials, NMN supplementation has been consistently shown to be safe and to reliably increase blood NAD+ levels. Functional benefits, while present in several studies, have been more modest and variable than might be expected from the animal data. Larger and longer-duration trials are underway and will be critical for determining whether NMN can deliver sustained, clinically significant health improvements in humans.

17. IV NAD+ Therapy

Intravenous NAD+ therapy has emerged as a popular offering in longevity clinics and wellness centers, where NAD+ is delivered directly into the bloodstream via an intravenous drip. Proponents argue that bypassing the digestive system allows NAD+ to be absorbed quickly and efficiently, achieving higher blood levels than oral supplementation. Typical IV NAD+ sessions last two to four hours and may involve 250 to 1,000 mg of NAD+ per infusion, with some protocols recommending multiple sessions over consecutive days.

The scientific evidence for IV NAD+ therapy is limited and the theoretical basis is debated. A significant concern is that NAD+ is a large, charged molecule that cannot easily cross cell membranes, raising questions about how much of the intravenously delivered NAD+ actually enters cells where it is needed. Some biochemists have criticized the approach, noting that NAD+ may need to be broken down into smaller precursors (such as NMN or NR) before it can be taken up by cells and used intracellularly. A 2019 pilot study in elderly adults found that repeated NAD+ infusions were well tolerated and safe, with participants experiencing improvements in certain metabolic markers and no serious adverse events. However, the study was small and did not include a placebo control group.

IV NAD+ therapy is not FDA-approved for any medical condition and exists in a regulatory gray area, offered under wellness frameworks rather than medical approval. Common side effects include temporary flushing, dizziness, nausea, headache, and discomfort at the IV site, all of which are generally transient and self-resolving. The cost of IV NAD+ therapy is substantially higher than oral supplementation, typically ranging from several hundred to over a thousand dollars per session. Given the limited evidence base and the availability of well-studied oral precursors, individuals considering IV NAD+ therapy should approach it with caution and be aware that the clinical evidence does not yet support the claims made by many providers.

18. Sublingual NMN vs Oral Supplementation

The NMN supplement market offers multiple delivery formats, with sublingual (under-the-tongue) and oral (capsule or powder) administration being the two most common. Marketing materials frequently claim that sublingual NMN offers dramatically superior bioavailability, with some sources citing 80 percent bioavailability for sublingual delivery versus 20 to 30 percent for oral capsules. However, it is important to note that no peer-reviewed human clinical trial has directly compared these two methods head-to-head.

The theoretical advantage of sublingual delivery is based on the anatomy of the oral mucosa. The tissue under the tongue is rich in blood vessels and has thin epithelium, allowing substances absorbed there to enter the bloodstream directly and bypass both the digestive system and first-pass liver metabolism. Sublingual NMN is reported to reach the bloodstream within 2.5 to 10 minutes. This route also completely bypasses the gut microbiota, which is significant given the discovery that gut bacteria convert a substantial portion of orally administered NMN to nicotinamide and nicotinic acid through deamidation.

However, the clinical significance of bypassing gut bacterial metabolism is uncertain. Research has shown that the bacterial conversion of NMN in the gut contributes to NAD+ production through alternative synthesis pathways, and blocking this process does not necessarily improve overall NAD+ outcomes. Several large human clinical trials using standard oral NMN capsules have confirmed that oral administration effectively boosts blood NAD+ levels, with some of the largest NMN studies to date demonstrating that NMN has strong absorption properties in the human digestive system. Liposomal formulations, which encapsulate NMN in lipid particles to protect against degradation, represent another delivery approach that is gaining commercial traction, though comparative human data remain limited. Until rigorous comparative trials are published, the choice between sublingual and oral NMN should be guided by personal preference, convenience, and tolerance rather than definitive claims of superiority.

19. Dosage and Timing

Determining the optimal dose of NMN is an area of active research, and recommendations vary based on the clinical evidence available. Human clinical trials have used doses ranging from 250 mg to 2,000 mg per day, with most studies finding NMN well tolerated across this range. The most commonly used dose in clinical research is 250 to 500 mg per day, which has been shown to reliably increase blood NAD+ levels. Higher doses of 600 to 1,200 mg per day have shown dose-dependent benefits for exercise performance in athletic populations, suggesting that optimal dosing may depend on the specific health goal.

Timing of supplementation may be important given the relationship between NAD+ metabolism and the circadian clock. The body's natural NAD+ levels peak in the morning and decline through the day, driven by the circadian oscillation of NAMPT expression. Taking NMN in the morning on an empty stomach aligns with this natural rhythm and may optimize absorption and utilization. Some researchers and practitioners recommend taking NMN first thing in the morning, at least 30 minutes before food, to maximize its integration with the body's metabolic and circadian machinery.

For those new to NMN supplementation, a prudent approach is to start at a lower dose (250 mg per day) and gradually increase to 500 mg or higher based on tolerance and response. Most clinical trials have run for 8 to 12 weeks, and the long-term effects of NMN supplementation beyond this timeframe are not yet well characterized in humans. Periodic monitoring of NAD+ levels through commercially available blood tests may help individuals assess their response and adjust dosing accordingly. As always, supplementation decisions should be made in consultation with a healthcare provider, particularly for individuals with existing medical conditions or those taking prescription medications.

20. Synergistic Supplements — Resveratrol, TMG, and Quercetin

Many researchers and longevity practitioners recommend combining NMN with complementary supplements that may enhance its effects through synergistic mechanisms. The three most commonly discussed synergistic compounds are resveratrol, trimethylglycine (TMG, also known as betaine), and quercetin.

Resveratrol

Resveratrol is a polyphenol found in red wine, grapes, and certain berries that has been identified as a sirtuin- activating compound (STAC). While NMN increases NAD+ levels (providing the fuel for sirtuins), resveratrol directly activates sirtuin enzymes, particularly SIRT1 (acting as the accelerator). Together, they may amplify each other's effects: NMN ensures there is sufficient NAD+ substrate, and resveratrol enhances the rate at which sirtuins use it. Research has suggested that resveratrol can increase sirtuin activity by up to 13-fold. Resveratrol is fat-soluble and should be taken with a meal containing healthy fats — such as nuts, avocado, or olive oil — to optimize absorption. Typical doses range from 250 to 1,500 mg per day.

Trimethylglycine (TMG)

TMG is a methyl donor that supports the methylation cycle, one of the most important biochemical processes in the body. When NMN is converted to NAD+ and subsequently used by sirtuins and other NAD+-consuming enzymes, nicotinamide is released as a byproduct. Nicotinamide must be methylated (by the enzyme NNMT, which requires methyl groups) before it can be excreted. High-dose NMN supplementation could theoretically deplete the body's methyl donor pool, potentially affecting DNA methylation, neurotransmitter synthesis, and homocysteine metabolism. TMG provides additional methyl groups to compensate for this increased demand. A common starting dose is 500 mg per day, with some users increasing to 1,000 mg per day. TMG is best taken in the morning alongside NMN.

Quercetin

Quercetin is a flavonoid found in onions, apples, and capers that has demonstrated potent senolytic activity — the ability to selectively eliminate senescent (aged, dysfunctional) cells that accumulate with age and secrete inflammatory molecules known as the senescence-associated secretory phenotype (SASP). By clearing senescent cells, quercetin may reduce the inflammatory burden that drives CD38 upregulation and NAD+ depletion, thereby indirectly supporting NAD+ levels. Quercetin also has anti-inflammatory, antioxidant, and mast cell-stabilizing properties. Typical supplemental doses range from 500 to 1,000 mg per day. Quercetin has relatively poor bioavailability on its own and is sometimes paired with bromelain or formulated in phytosomal preparations to improve absorption.

21. Safety and Side Effects

The safety profile of NMN supplementation in humans has been reassuring across the clinical trials conducted to date. Across human trials lasting 8 to 12 weeks at doses of 250 to 900 mg per day, and in short-term safety studies at doses up to 1,250 mg per day for four weeks, NMN has been generally well tolerated with no serious adverse events reported. High-dose studies using up to 2,000 mg per day have also not reported serious adverse effects. In a pooled analysis, a total of approximately 8 percent of participants reported any adverse event, but none were categorized as severe.

The most commonly reported side effects are mild and transient, including gastrointestinal discomfort (nausea, diarrhea, abdominal pain), headache, skin reactions (hives), and cold-like symptoms. These effects are generally self-limiting and resolve without intervention. Some individuals report a sensation of increased energy or mild flushing, particularly with higher doses, which may reflect the rapid increase in NAD+ availability and enhanced metabolic activity.

A significant limitation of the current safety data is the relatively short duration of existing trials. Most studies have run for 8 to 12 weeks, and the longest published NMN trial extended to 24 weeks. The long-term safety of NMN supplementation over years or decades is unknown. There have been theoretical concerns about whether chronically elevated NAD+ levels could promote the growth of existing but undetected cancers, since cancer cells are metabolically active and could potentially benefit from enhanced NAD+ availability. However, this concern remains speculative, and some researchers argue that the enhanced DNA repair and immune surveillance enabled by NAD+ restoration would have a net protective effect. Until longer-term data are available, individuals taking NMN should maintain regular health screenings and discuss supplementation with their healthcare providers.

22. Regulatory Status

The regulatory history of NMN in the United States has been turbulent. In November 2022, the FDA announced that NMN could not be sold as a dietary supplement ingredient, citing its prior investigation as a new drug by Metro International Biotech, a pharmaceutical company co-founded by David Sinclair. Under the Federal Food, Drug, and Cosmetic Act, a substance that has been authorized for investigation as a new drug may be excluded from the definition of a dietary supplement if it was not marketed as a supplement before the drug investigation began. This determination effectively threatened to remove NMN from the supplement market in the United States and provoked significant controversy and legal action from the supplement industry.

On September 29, 2025, following pressure from the Natural Products Association (NPA) and other industry groups, the FDA reversed its position and confirmed that beta-nicotinamide mononucleotide (NMN) is lawful for use in dietary supplements. The reversal centered on the FDA's analysis of the "race to market" provision, which allows a substance to be sold as a dietary supplement if it was marketed as such before it was authorized for drug investigation. The Agency concluded that sufficient evidence exists showing NMN was marketed as a dietary supplement in the United States before the drug investigation authorization, thereby qualifying for the exemption. In December 2025, the FDA issued additional letters to ingredient manufacturers SyncoZymes and Inner Mongolia Kingdomway confirming that NMN is no longer excluded from the dietary supplement definition.

Despite this favorable determination, NMN remains classified as a New Dietary Ingredient (NDI), meaning that companies must submit a New Dietary Ingredient Notification (NDIN) to the FDA before marketing NMN products, unless their ingredient is sourced from a supplier that has already filed an accepted NDIN. Internationally, the regulatory landscape varies considerably. Japan and South Korea have well-established consumer markets for NMN longevity products. China has approved NMN as a cosmetic ingredient. The European Union has not yet established a specific regulatory framework for NMN as a supplement. Consumers should purchase NMN products from reputable manufacturers that provide third-party testing for purity and potency, as the quality of NMN supplements can vary significantly across the market.

References

1. Harden, A., Young, W.J. (1906). The Alcoholic Ferment of Yeast-Juice. Proceedings of the Royal Society of London B, 77(519), 405–420.
2. Yoshino, J., Baur, J.A., Imai, S. (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism, 27(3), 513–528.
3. Camacho-Pereira, J., et al. (2016). CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction Through a SIRT3-Dependent Mechanism. Cell Metabolism, 23(6), 1127–1139.
4. Imai, S., Guarente, L. (2014). NAD+ and Sirtuins in Aging and Disease. Trends in Cell Biology, 24(8), 464–471.
5. Mills, K.F., et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism, 24(6), 795–806.
6. Yoshino, M., et al. (2021). Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women. Science, 372(6547), 1224–1229.
7. Liao, B., et al. (2021). Nicotinamide Mononucleotide Supplementation Enhances Aerobic Capacity in Amateur Runners: A Randomized, Double-Blind Study. Journal of the International Society of Sports Nutrition, 18(1), 54.
8. Bertoldo, M.J., et al. (2020). NAD+ Repletion Rescues Female Fertility During Reproductive Aging. Cell Reports, 30(6), 1670–1681.
9. Miao, Y., et al. (2020). Nicotinamide Mononucleotide Supplementation Reverses the Declining Quality of Maternally Aged Oocytes. Cell Reports, 32(5), 107987.
10. Tarantini, S., et al. (2019). Nicotinamide Mononucleotide (NMN) Supplementation Rescues Cerebromicrovascular Endothelial Function and Neurovascular Coupling Responses and Improves Cognitive Function in Aged Mice. Redox Biology, 24, 101192.
11. Nakahata, Y., et al. (2009). Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1. Science, 324(5927), 654–657.
12. Ramsey, K.M., et al. (2009). Circadian Clock Feedback Cycle Through NAMPT-Mediated NAD+ Biosynthesis. Science, 324(5927), 651–654.
13. Martens, C.R., et al. (2018). Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults. Nature Communications, 9(1), 1286.
14. Yi, L., et al. (2023). The Efficacy and Safety of Beta-Nicotinamide Mononucleotide (NMN) Supplementation in Healthy Middle-Aged Adults. GeroScience, 45(1), 29–43.
15. Pencina, K.M., et al. (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of Beta-Nicotinamide Mononucleotide, Increases Circulating NMN and NAD in a Randomized Clinical Trial. The Journals of Gerontology: Series A, 78(1), 90–96.
16. Shade, C. (2020). The Science Behind NMN–A Stable, Reliable NAD+ Activator and Anti-Aging Molecule. Integrative Medicine, 19(1), 36–41.
17. Covarrubias, A.J., et al. (2021). NAD+ Metabolism and Its Roles in Cellular Processes During Ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141.
18. Verdin, E. (2015). NAD+ in Aging, Metabolism, and Neurodegeneration. Science, 350(6265), 1208–1213.
19. Bonkowski, M.S., Sinclair, D.A. (2016). Slowing Ageing by Design: The Rise of NAD+ and Sirtuin-Activating Compounds. Nature Reviews Molecular Cell Biology, 17(11), 679–690.
20. Kane, A.E., Sinclair, D.A. (2018). Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases. Circulation Research, 123(7), 868–885.
21. Walker, M.A., Bhargava, R. (2025). Clinical Evidence for the Use of NAD+ Precursors to Slow Aging. Geromedicine, 1(1), 0008.
22. Yang, Y., et al. (2025). An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR). Food Frontiers, 6(1), e511.
23. U.S. Food and Drug Administration. (2025). NMN Dietary Supplement Determination Letters.

Back to Table of Contents